Ultragenyx Reports the EC’s Approval of Evkeeza (evinacumab) to Treat 6-Months Old Children with Homozygous Familial Hypercholesterolemia (HoFH)
Shots:
- The EC has approved Evkeeza (an angiopoietin-like 3 inhibitor), as an adjunct to diet & other lipid-lowering therapies, to treat children (6mos. to 5yrs.) with HoFH
- Approval was based on model-based analysis that predicted similar or greater LDL-C reductions with Evkeeza (15mg/kg, Q4W) in children (6mos. to 5yrs.) at 24wks. Data from compassionate use in 5 children (1-4yrs.) depicted meaningful LDL-C reduction, consistent with older pediatric patients (≥5yrs.)
- Evkeeza is approved for HoFH patients (≥12yrs.), with the indication extending to ages 5-11yrs. in Dec 2023. It is now reimbursed & available in the US, UK, Canada, Japan & several EU countries, with early access in 13 other regions incl. Austria & France
Ref: GlobeNewswire | Image: Ultragenyx
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
